SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena > Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

$COCK is trending due to community enthusiasm around its real-world asset integration with Cocky Wings, a food truck business that fuels token buybacks, and the recent announcement of a partnership with $SNEK energy drinks. The community is actively discussing locking tokens for passive income and participating in the COCK Arena, while also anticipating more buybacks and new locations for Cocky Wings. This memecoin is aiming to revolutionize MemeFi on Cardano with a unique blend of on-chain hype and off-chain revenue.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

BETR is trending due to excitement around its AI-driven mortgage platform, with community members discussing its potential to disrupt the lending industry. Investors are analyzing recent partnerships and revenue forecasts, while also weighing potential risks like share dilution. Bullish sentiment is fueled by comparisons to high-growth tech companies and anticipation of future rate cuts.

Volatility Shares Trust - Volatility Shares Trust XRP ETF

XRP ETF

XRPI is trending amid discussions about potential benefits from Ripple's partnerships and speculation around asset tokenization. Community members are actively discussing its possible adoption by banks and its potential as a long-term investment within the cryptocurrency space. The possibility of an XRP ETF approval in the US is also a key catalyst driving interest.

HCM II Acquisition Corp. operates as a blank check company. It was formed for the purpose of entering into a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on April 4, 2024 and is headquartered in Stamford, CT.

HCM II Acquisition Corp - Ordinary Shares - Class A

HCM II Acquisition Corp.

HCM II Acquisition Corp. ($HOND) is trending as the merger with Terrestrial Energy approaches, anticipated to finalize around October 28th, with the new ticker $IMSR. The community is weighing the potential for a post-merger drop, typical of SPACs, against the long-term prospects of Terrestrial Energy's advanced nuclear technology, particularly in comparison to sector peer $OKLO. Many believe the new ticker and growing interest in nuclear energy could drive the stock price higher, citing its potential in edge energy markets and backing from government programs.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix (CRMD) is trending due to anticipation surrounding potential catalysts, including the upcoming Q3 earnings report and real-world evidence data for DefenCath. Community discussions revolve around revenue guidance, the impact of the Melinta acquisition, and speculation about a potential short squeeze. Investors are also closely monitoring CRMD's strategic investment in Talphera (TLPH) and its potential for future growth.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

SNDX is trending due to discussions around its recent FDA approval for Revuforj, a leukemia drug, and its competitive positioning against KURA. The community is weighing the drug's efficacy against safety concerns highlighted by a black box warning, while some speculate about a potential buyout before 2027. Bullish investors suggest this pullback is a buying opportunity, anticipating positive earnings and future analyst upgrades.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending as investors analyze its upcoming earnings report and recent analyst ratings, with community members discussing potential price movements. Concerns around transaction revenues and the competitive landscape are top of mind, while some are optimistic about long-term growth due to buybacks and strategic initiatives. Traders are also monitoring technical indicators and potential swing trading opportunities.

iRobot Corp. is a robot company, which engages in designing and building robots. The firm's products include robot vacuums and maps, and pool cleaners. It operates through Domestic and International geographical segments. The company was founded by Rodney Allen Brooks, Colin M. Angle, and Helen Greiner in August 1990 and is headquartered in Bedford, MA.

Irobot Corp

iRobot Corp

IRBT is trending as traders discuss its potential for a short squeeze, drawing parallels to recent rallies in other heavily shorted stocks. Community members are highlighting its high short interest and low float as key factors, while also noting potential catalysts such as debt restructuring and renewed interest in robotics and AI. Some are speculating on a potential buyout, reminiscent of Amazon's previous attempt.

Payoneer Global, Inc. is a financial technology company, which engages in providing a financial platform for small and medium-sized businesses to transact and do business. It operates through the Israel, United States, and All Other Countries geographical segments. The company was founded in 2005 and is headquartered in New York, NY.

Payoneer Global Inc

Payoneer is trending as investors discuss its valuation and potential for growth within the fintech sector. The company's fundamentals and a recent analyst upgrade are being weighed against concerns about management's communication strategy and the overall market sentiment towards fintech stocks. Some investors speculate on potential acquisitions or strategic moves to unlock value.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing ($RGTI) is trending amid mixed sentiment and high volatility, driven by discussions around government funding, insider selling, and technical analysis patterns. The community is debating the company's valuation, future prospects, and potential competition from larger tech companies like IBM and Google. Bears point to weak revenue and director selling, while bulls highlight potential breakthroughs and government interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Harmony Biosciences (HRMY) Moves 12.7% Higher: Will This Strength Last?

Harmony Biosciences (HRMY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

<ul class="summary-bullets"><li>The company now expects full-year revenue to be $845 million to $865 million, up from the previous range of $820 million to $860 million.</li><li>It said that the Wakix franchise delivered net revenue of approximately $239 million in the third quarter.&nbsp;</li></ul>Shares of Harmony Biosciences Holdings (HRMY) jumped 6% in the premarket session on Thursday after the company raised its full-year revenue guidance on strong Wakix sales.The firm now <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251023496242/en/Harmony-Biosciences-Preannounces-Strong-Q3-2025-WAKIX-Performance-Raises-2025-Revenue-Guidance">expects</a> full-year revenue to be $845 million to $865 million, up from the previous range of $820 million to $860 million.<h2 class="st-heading-2">Excessive Sleepiness Medication Drives Revenue</h2>The company said that its Wakix franchise delivered net revenue of approximately $239 million in the third quarter (Q3), representing 29% year-over-year revenue growth. Wakix is approved by the U.S. Food and Drug Administration for the treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy and for the treatment of EDS in pediatric patients six years of age and older with narcolepsy.Narcolepsy is a chronic neurological disorder affecting the brain's ability to regulate sleep-wake cycles, causing excessive daytime sleepiness and uncontrollable sleep attacks. Other symptoms include sudden loss of muscle control called cataplexy. The company said the increase in Wakix revenue was driven by higher average patient volume.The company is expected to report full Q3 earnings on November 4.<h2 class="st-heading-2">What Are Stocktwits Users Saying?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HRMY">HRMY stock</a> jumped from ‘bearish’ to ‘neutral’ over the past 24 hours, while message volume remained at ‘low’ levels.Last month, the company <a href="https://stocktwits.com/news-articles/markets/equity/harmony-biosciences-stock-slumps-after-rare-genetic-disorder-drug-fails-late-stage-study/chD1BhBR3Ed">announced</a> that its late-stage study of ZYN002 in Fragile X syndrome did not meet the primary endpoint of improvement in social avoidance due to a higher-than-expected placebo response rate. Fragile X syndrome (FXS) is a rare genetic disorder that negatively affects synaptic function, plasticity, and neuronal connections. It results in a spectrum of intellectual disabilities and behavioral symptoms, such as social avoidance and irritability.CEO Jeffrey M. Dayno then highlighted the company’s strong portfolio, noting that it is on track to initiate late-stage trials of Wakix in narcolepsy and idiopathic hypersomnia in the fourth quarter of this year.HRMY shares are down 24% this year and by about 23% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-recalls-nearly-64000-cybertrucks-over-concerns-with-front-parking-lights/cLG4hXGR3AH">Tesla Recalls Nearly 64,000 Cybertrucks Over Concerns With The Front Parking Lights</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Harmony Biosciences Raises Full-Year Revenue Guidance Ahead Of Earnings: Why Are Wakix Franchise Numbers Crucial?

The company now expects full-year revenue to be $845 million to $865 million, up from the previous range of $820 million to $860 million.

Equity

Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced preliminary results for Q3 2025, highlighted by the following: WAKIX (pitolisant) franchise delivered net revenue of approximately...

Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates

Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of -22.62% and -57.71%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?

HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal

Harmony Biosciences' shares plunge after ZYN002 failed in Fragile X, but Wakix sales and new epilepsy assets keep its pipeline moving forward.

Harmony Biosciences Holdings (HRMY) on Wednesday said that its late-stage study of ZYN002 in Fragile X syndrome did not meet the primary endpoint of improvement in social avoidance.Fragile X syndrome (FXS) is a rare genetic disorder that negatively affects synaptic function, plasticity, and neuronal connections. It results in a spectrum of intellectual disabilities and behavioral symptoms, such as social avoidance and irritability. According to the company, the disease affects upwards of 80,000 patients in the U.S. and 121,000 patients in the European Union and the U.K. The disease is more common in males than females, but there are no FDA-approved treatments for the disorder.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.harmonybiosciences.com/news-releases/news-release-details/harmony-biosciences-provides-update-its-phase-3-reconnect-study">said</a> on Wednesday that its drug did not meet the primary endpoint of the trial primarily due to a higher-than-expected placebo response rate.Shares of HRMY traded 15% lower at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HRMY">HRMY stock</a> rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:575/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_24_at_1_01_23_PM_png_17fb739829.webp" alt="HRMY's Sentiment Meter and Message Volume as of 1:01 p.m. ET on Sept. 24, 2025 | Source: Stocktwits" width="575" height="62"><figcaption>HRMY's Sentiment Meter and Message Volume as of 1:01 p.m. ET on Sept. 24, 2025 | Source: Stocktwits</figcaption></figure>Chief Medical Officer Kumar Budur stated that, although the study's findings did not meet the primary endpoint, they provide valuable insights into Fragile X syndrome. “We will conduct a comprehensive analysis of the full dataset to better understand the results as part of our continued commitment to the Fragile X community,” Budur said.The trial, which enrolled 215 patients with FXS aged 3 to under 30 years, aimed to assess the efficacy and safety of ZYN002, a pharmaceutically manufactured synthetic cannabidiol.CEO Jeffrey M. Dayno stated that the company has additional candidates in its pipeline. “We have a late-stage, catalyst-rich pipeline with multiple Phase 3 programs in the clinic and continue to be on track to initiate our Phase 3 trials for pitolisant HD in narcolepsy and idiopathic hypersomnia in the fourth quarter of this year,” he said.HRMY stock is down by 21% this year and by 28% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/honda-motor-reportedly-ends-us-production-of-acura-zdx-ev/chD14gFR33x">Honda Motor Reportedly Ends US Production Of Acura ZDX EV</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Harmony Biosciences Stock Slumps After Rare Genetic Disorder Drug Fails Late-Stage Study

The company said on Wednesday that its drug did not meet the primary endpoint of the trial primarily due to a higher-than-expected placebo response rate.

Can Cannabis Stocks Reverse Their Prolonged Downtrend?

Cannabis stocks like TLRY and GTBIF remain deep in years-long slump, but U.S. federal reform or global expansion could ignite a long-awaited rebound.

Harmony Biosciences Holdings, Inc. (HRMY) Misses Q2 Earnings and Revenue Estimates

Harmony Biosciences (HRMY) delivered earnings and revenue surprises of -12.82% and -1.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for

Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Harmony Biosciences Holdings, Inc. (HRMY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the provision of development and commercialization of therapies for the treatment of neurological disorders. Its product, WAKIX, is a molecule with a novel mechanism of action designed to increase histamine signaling in the brain by binding to H3 receptors. The company was founded by Jeffrey S. Aronin on July 25, 2017 and is headquartered in Plymouth Meeting, PA.

Harmony Biosciences Holdings Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

HRMY
Harmony Biosciences Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HRMY News

HRMYHarmony Biosciences Holdings Inc